Gastroparesis

Gastroenterology
9
Pipeline Programs
9
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
7
0
0
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
1
CisapridePhase 41 trial
Active Trials
NCT01281540Terminated20Est. Nov 2003
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
Immediate-release omeprazolePhase 4Small Molecule1 trial
Active Trials
NCT00492622CompletedEst. Dec 2008
VP
Vanda PharmaceuticalsWASHINGTON, DC
2 programs
1
VLY-686Phase 21 trial
TradipitantN/A1 trial
Active Trials
NCT04474990Available
NCT02970968Completed152Est. Dec 2018
PTC Therapeutics
1 program
1
CNSA-001Phase 21 trial
Active Trials
NCT03712124Completed21Est. Oct 2019
CP
Chugai PharmaJapan - Tokyo
1 program
1
GM-611Phase 21 trial
Active Trials
NCT00050882Completed
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
1
GranisetronPhase 21 trial
Active Trials
NCT04501211Withdrawn0Est. Dec 2021
Recordati
RecordatiFrance - Saint-Victor
1 program
1
HeminPhase 21 trial
Active Trials
NCT01206582Completed20Est. Dec 2014
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Naloxegol 25 MG Oral Tablet [Movantik]Phase 21 trial
Active Trials
NCT03036891Withdrawn0Est. Sep 2019
Processa Pharmaceuticals
1 program
1
PCS12852Phase 21 trial
Active Trials
NCT05270460Completed25Est. Oct 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthImmediate-release omeprazole
Johnson & JohnsonCisapride
Processa PharmaceuticalsPCS12852
PTC TherapeuticsCNSA-001
Kyowa Hakko KirinGranisetron
AstraZenecaNaloxegol 25 MG Oral Tablet [Movantik]
Vanda PharmaceuticalsVLY-686
RecordatiHemin

Clinical Trials (10)

Total enrollment: 238 patients across 10 trials

NCT00492622Bausch HealthImmediate-release omeprazole

Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis

Start: Jun 2007Est. completion: Dec 2008
Phase 4Completed
NCT01281540Johnson & JohnsonCisapride

An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options

Start: May 2003Est. completion: Nov 200320 patients
Phase 4Terminated
NCT00050882Chugai PharmaGM-611

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

Phase 2Completed
NCT05270460Processa PharmaceuticalsPCS12852

Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis

Start: Mar 2022Est. completion: Oct 202225 patients
Phase 2Completed
NCT03712124PTC TherapeuticsCNSA-001

A Study of CNSA-001 in Women With Diabetic Gastroparesis

Start: Feb 2019Est. completion: Oct 201921 patients
Phase 2Completed
NCT04501211Kyowa Hakko KirinGranisetron

Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis

Start: Jan 2019Est. completion: Dec 20210
Phase 2Withdrawn
NCT03036891AstraZenecaNaloxegol 25 MG Oral Tablet [Movantik]

Naloxegol for Opioid-Related Gastroparesis

Start: Dec 2016Est. completion: Sep 20190
Phase 2Withdrawn
NCT02970968Vanda PharmaceuticalsVLY-686

Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

Start: Nov 2016Est. completion: Dec 2018152 patients
Phase 2Completed
NCT01206582RecordatiHemin

A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

Start: May 2010Est. completion: Dec 201420 patients
Phase 2Completed
NCT04474990Vanda PharmaceuticalsTradipitant

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

N/AAvailable

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)